In contrast, isogenic double mutant BRAF V600E MEK1 Q56P cells did not exhibit reduced RSK phosphorylation following BRAF or MEK inhibitor treatment, while BVD 523 remained effective in inhibiting pRSK1 2 to a level comparable to parental RKO doxycycline for rosacea